The FDA nod “represents an important first step that will one day allow our technology to help many people,” Neuralink said in a tweet. It did not elaborate on the aims of the study, saying only that it was not recruiting yet and more details would be available soon.

In the coming months, Vivus plans to launch its pill, sold as Qsiva in Europe and Qysmia in the U.S., in Sweden, Norway, Denmark, Finland and Iceland. It already has regulatory approval in the U.S., Poland and South Korea, as well as these countries.

Novo Nordisk and Pfizer separately released data on Monday showing that pills from the same class as Novo’s increasingly popular weight loss drugs such as Wegovy are about as effective as those injected medicines, giving shares of both companies a boost.

Denmark’s Zealand Pharma and Boehringer Ingelheim said their experimental obesity treatment achieved up to 14.9% weight loss in a mid-stage trial, lining up a potential contestant in the booming obesity drug market.

Buoyed by the success of its diabetes and obesity drugs, Novo Nordisk is on the prowl for partnerships and deals to beef up its pipeline, a senior company executive said on Thursday.

Denmark’s largest private health insurer Sygeforsikring Danmark, which insures roughly half the country’s population, will stop reimbursing weight loss medication from January next year due to high demand, it said on Friday.

The new partnership involves an initial payout of $75 million and the potential for up to $2.6 billion in milestone funding.

Should they be used broadly, along with diet and exercise? Or should higher risk patients with other conditions be prioritized?

Patients discontinuing the use of weight-loss drugs such as Wegovy risk regaining their original body weight in about five years, a company official said on Wednesday.

The request to consider obesity drugs was submitted by three doctors and a researcher in the United States and covers the active ingredient liraglutide in Novo Nordisk’s obesity drug Saxenda, which will come off patent soon, allowing for cheaper generic versions.